Pharmacokinetic and Pharmacodynamic of Rocuronium

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is characterize the dose-effect relationship of rocuronium bromide at the adductor pollicis and masseter muscles using an pharmacokinetic-pharmacodynamic (PKPD) model. The hypothesis is that masseter muscle has a greater sensitivity to the neuromuscular blockers (rocuronium), faster onset and slower recovery profile than the adductor pollicis muscle.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pontificia Universidad Catolica de Chile
• Treatments: Bromides; Rocuronium

Criteria

Inclusion Criteria:

• Scheduled for elective surgery under general anesthesia.

Exclusion Criteria:

• Pregnancy.

• Body mass index (BMI) >25 kg/m2.

• Anticipated difficult airway.

• Surgery associated with great volume loss.

• Presence of any neuromuscular, hepatic, renal, cardiac or respiratory disease.

• Previous history of neuromuscular blockade allergy, and/or administration of drugs known to interfere with neuromuscular blockade